Related Experiment Videos
Effect of anethole dithiolthione on human platelet aggregation
M L Selley1, J A McGuiness, M R Bartlett
1Australian National University, John Curtin School of Medical Research, Division of Clinical Sciences, Garran, A.C.T.
Arzneimittel-Forschung
|March 1, 1992
Summary
Anethole dithiolthione (ADT) inhibits platelet aggregation by blocking thromboxane synthesis and preventing arachidonic acid release. This compound shows potential in preventing blood clot formation.
Area of Science:
- Pharmacology
- Biochemistry
- Hematology
Background:
- Platelet aggregation is crucial for hemostasis but also implicated in thrombosis.
- Thromboxane (Tx)B2 and arachidonic acid (AA) release are key mediators of platelet activation.
- Anethole dithiolthione (ADT) is a compound with potential antiplatelet properties.
Purpose of the Study:
- To investigate the effects of Anethole dithiolthione (ADT) on platelet aggregation and related signaling pathways.
- To determine the mechanism by which ADT influences platelet activation.
Main Methods:
- Platelet aggregation assays were performed using various agonists like adenosine diphosphate (ADP), epinephrine, arachidonic acid (AA), thrombin, and collagen.
- Thromboxane B2 (TxB2) formation and 3H-AA release from platelet phospholipids were measured.
- The effects of ADT were compared with acetylsalicylic acid and butylated hydroxytoluene.
Main Results:
- ADT inhibited platelet aggregation and TxB2 formation induced by ADP, epinephrine, and AA.
- Partial inhibition was observed with thrombin, phorbol myristate acetate, and calcium ionophore A23187.
- ADT increased lag time for collagen-induced aggregation and inhibited AA release from phospholipids.
Conclusions:
- Anethole dithiolthione (ADT) effectively inhibits platelet aggregation.
- The mechanism involves the inhibition of thromboxane synthesis and prevention of arachidonic acid release.
- ADT demonstrates significant potential as an antiplatelet agent.